Literature DB >> 30223190

Initiation and engagement as mechanisms for change caused by collaborative care in opioid and alcohol use disorders.

Claude M Setodji1, Katherine E Watkins2, Sarah B Hunter3, Colleen McCullough4, Bradley D Stein5, Karen Chan Osilla6, Allison J Ober7.   

Abstract

BACKGROUND: To assess the mechanism by which a collaborative care (CC) intervention improves self-reported abstinence among primary care patients with opioid and alcohol use disorders (OAUD) compared to treatment as usual.
METHODS: Secondary data analysis of SUMMIT, a randomized controlled trial of CC for OAUD. Participants were 258 patients with OAUD receiving primary care at a multi-site Federally Qualified Health Center. Using a mediation analysis decomposition of a total effect into a mediated and a direct effect, we examined the effect of CC on abstinence at six months, attributable to the HEDIS treatment initiation and engagement measures for the total sample, for individuals with alcohol use disorders alone, and for those with a co-morbid opioid use disorder.
RESULTS: Although the CC intervention led to an increase in both initiation and engagement, among the full sample, only initiation mediated the effect of the intervention on abstinence (3.8%, CI=[0.4%, 8.3%]; 32% proportion of the total effect). In subgroup analyses, among individuals with comorbid alcohol and opioid use disorders, almost 100% of the total effect was mediated by engagement, but the effect was not significant. This was not observed among the alcohol use disorder only group.
CONCLUSIONS: Among primary care patients with OAUDs, treatment initiation partially mediated the effect of CC on abstinence at 6-months. The current study emphasizes the importance of primary care patients returning for a second substance-use related visit after identification. CC may work differently for people with co-morbid opioid use disorders vs. alcohol use disorders alone.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Collaborative care intervention; Engagement; Mediation; Opioid and alcohol use disorders; Treatment initiation

Mesh:

Substances:

Year:  2018        PMID: 30223190      PMCID: PMC6334843          DOI: 10.1016/j.drugalcdep.2018.07.027

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  1 in total

1.  Exploring the Role of Alcohol Metabolizing Genotypes in a 12-Week Clinical Trial of Naltrexone for Alcohol Use Disorder.

Authors:  João M Castaldelli-Maia; André Malbergier; Adriana B P de Oliveira; Ricardo A Amaral; André B Negrão; Priscila D Gonçalves; Antonio Ventriglio; Domenico de Berardis; Juliana de Antonio; Isabela Firigato; Gilka J F Gattás; Fernanda de Toledo Gonçalves
Journal:  Biomolecules       Date:  2021-10-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.